CTRI/2022/03/040738已完成不适用
Evaluation of Skin Safety of 2 test product for Primary Skin Irritation Using Skin Irritation Test (Patch Test in Humans) IS 4011:2018 Guidelines.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Evaluation of cutaneous tolerance of skin reactions (erythema, oedema, dryness, scaling, wrinkling), using Draize scale.
研究概览
简要总结
The test products,
• MINOXIFIN B. No: MFI21001
• Minoxidil Foam 5% w/w B. No: PAL/MOFF-E/22/001
were dermatologically tested and found to be “Non-Irritant†based on IS 4011 :2018, Methods of Test for safety evaluation of cosmetics -Third Revision.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Voluntary men and women (preferably equal number of males and females) between 18 and 65 years.
- •Fitzpatrick skin type III to IV.
- •Having apparently healthy skin on test area.
- •Willingness to discontinue the use of cleansing and/or cosmetic products in the application areas during the course of the trial
- •Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures.
- •Willing to give written informed consent to participate in the trial after informing all information concerning the trial procedures and trial objectives.
- •Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course of the trial.
- •Should be able to read and write (in English, Hindi, or local language).
- •Ready to wear loose cotton clothes
- •Having valid proof of identity and age.
- •Having not participated in another trial in the past one month.
排除标准
- •Pregnancy (by history) and lactating women.
- •Scars, excessive terminal hair, or tattoo on the studied area.
- •A participant who the Investigator feels will not be compliant with trial requirements
- •Dermatological infection/pathology on the level of studied area.
- •Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye).
- •Any clinically significant systemic or cutaneous disease, which may interfere with trial procedures.
- •Chronic illness which may influence the outcome of the trial.
- •Participants on any medical treatment either systemic or topical which may interfere with the performance of the trial (presently or in the past 1 month).
- •Participant in an exclusion period or participating in another food, cosmetic or therapeutic trial.
结局指标
主要结局
Evaluation of cutaneous tolerance of skin reactions (erythema, oedema, dryness, scaling, wrinkling), using Draize scale.
时间窗: 48 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
To test the safety of a test product in healthy human volunteers.CTRI/2022/01/039409CIPLA LTD50
已完成
不适用
To test the safety of 3 test products for skin irritationCTRI/2021/03/032023Sun Pharmaceutical Industries Ltd60
已完成
不适用
To check the safety of 1 test product for skin irritationCTRI/2021/04/033255Apex Laboratories Pvt Ltd28
已完成
不适用
To evaluate safety of a test product for skin irritatioCTRI/2022/06/043046Cipla Ltd52
已完成
不适用
To test the safety of a test product in healthy human volunteers.CTRI/2022/01/039409CIPLA LTD52